IPSEN (IPN.PA) Stock Fundamental Analysis
EPA:IPN - Euronext Paris - Matif - FR0010259150 - Common Stock - Currency: EUR
Taking everything into account, IPN scores 5 out of 10 in our fundamental rating. IPN was compared to 52 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of IPN get a neutral evaluation. Nothing too spectacular is happening here. IPN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year IPN was profitable.
In the past year IPN had a positive cash flow from operations.
In the past 5 years IPN has always been profitable.
IPN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of IPN (8.97%) is better than 73.08% of its industry peers.
The Return On Equity of IPN (13.82%) is better than 63.46% of its industry peers.
IPN has a better Return On Invested Capital (18.58%) than 88.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.97% | ||
| ROE | 13.82% | ||
| ROIC | 18.58% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IPN has a Profit Margin of 10.85%. This is comparable to the rest of the industry: IPN outperforms 57.69% of its industry peers.
In the last couple of years the Profit Margin of IPN has declined.
IPN has a Operating Margin of 20.90%. This is comparable to the rest of the industry: IPN outperforms 59.62% of its industry peers.
IPN's Operating Margin has declined in the last couple of years.
The Gross Margin of IPN (82.44%) is better than 86.54% of its industry peers.
IPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.9% | ||
| PM (TTM) | 10.85% | ||
| GM | 82.44% |
OM growth 3Y-10.65%
OM growth 5Y-2.1%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
2. Health
2.1 Basic Checks
IPN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
There is no outstanding debt for IPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
An Altman-Z score of 4.02 indicates that IPN is not in any danger for bankruptcy at the moment.
IPN's Altman-Z score of 4.02 is fine compared to the rest of the industry. IPN outperforms 67.31% of its industry peers.
The Debt to FCF ratio of IPN is 4.08, which is a neutral value as it means it would take IPN, 4.08 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.08, IPN is in line with its industry, outperforming 59.62% of the companies in the same industry.
IPN has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of IPN (0.09) is better than 78.85% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 4.08 | ||
| Altman-Z | 4.02 |
ROIC/WACC2.37
WACC7.83%
2.3 Liquidity
A Current Ratio of 1.34 indicates that IPN should not have too much problems paying its short term obligations.
IPN has a Current ratio (1.34) which is in line with its industry peers.
A Quick Ratio of 1.15 indicates that IPN should not have too much problems paying its short term obligations.
The Quick ratio of IPN (1.15) is better than 71.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.15 |
3. Growth
3.1 Past
The earnings per share for IPN have decreased strongly by -10.38% in the last year.
IPN shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.86% yearly.
IPN shows a strong growth in Revenue. In the last year, the Revenue has grown by 61.09%.
Measured over the past years, IPN shows a small growth in Revenue. The Revenue has been growing by 5.83% on average per year.
EPS 1Y (TTM)-10.38%
EPS 3Y-18.86%
EPS 5YN/A
EPS Q2Q%-22.76%
Revenue 1Y (TTM)61.09%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%112.35%
3.2 Future
Based on estimates for the next years, IPN will show a small growth in Earnings Per Share. The EPS will grow by 3.96% on average per year.
IPN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.50% yearly.
EPS Next Y7.55%
EPS Next 2Y7.48%
EPS Next 3Y8.47%
EPS Next 5Y3.96%
Revenue Next Year7.41%
Revenue Next 2Y6.57%
Revenue Next 3Y6.68%
Revenue Next 5Y3.5%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 15.92, the valuation of IPN can be described as correct.
Based on the Price/Earnings ratio, IPN is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 29.35. IPN is valued slightly cheaper when compared to this.
A Price/Forward Earnings ratio of 10.66 indicates a reasonable valuation of IPN.
IPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IPN is cheaper than 76.92% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.10. IPN is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.92 | ||
| Fwd PE | 10.66 |
4.2 Price Multiples
96.15% of the companies in the same industry are more expensive than IPN, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IPN indicates a slightly more expensive valuation: IPN is more expensive than 61.54% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 69.32 | ||
| EV/EBITDA | 4.98 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of IPN may justify a higher PE ratio.
PEG (NY)2.11
PEG (5Y)N/A
EPS Next 2Y7.48%
EPS Next 3Y8.47%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.25%, IPN has a reasonable but not impressive dividend return.
Compared to an average industry Dividend Yield of 2.86, IPN has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.33, IPN's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.25% |
5.2 History
The dividend of IPN has a limited annual growth rate of 3.76%.
Dividend Growth(5Y)3.76%
Div Incr Years0
Div Non Decr Years3
5.3 Sustainability
IPN pays out 17.23% of its income as dividend. This is a sustainable payout ratio.
IPN's earnings are growing around the same pace than its dividend. As long as the earnings growth is kept the dividend growth is sustainable.
DP17.23%
EPS Next 2Y7.48%
EPS Next 3Y8.47%
EPA:IPN (3/7/2025, 7:00:00 PM)
110
-2 (-1.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners14.93%
Inst Owner ChangeN/A
Ins Owners0.24%
Ins Owner ChangeN/A
Market Cap9.22B
Analysts67.37
Price Target127.81 (16.19%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.25% |
Yearly Dividend1.21
Dividend Growth(5Y)3.76%
DP17.23%
Div Incr Years0
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.63%
PT rev (3m)-1.64%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.78%
EPS NY rev (3m)0.94%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.56%
Revenue NY rev (3m)1.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.92 | ||
| Fwd PE | 10.66 | ||
| P/S | 1.73 | ||
| P/FCF | 69.32 | ||
| P/OCF | 10.07 | ||
| P/B | 2.2 | ||
| P/tB | 9.57 | ||
| EV/EBITDA | 4.98 |
EPS(TTM)6.91
EY6.28%
EPS(NY)10.32
Fwd EY9.38%
FCF(TTM)1.59
FCFY1.44%
OCF(TTM)10.92
OCFY9.93%
SpS63.55
BVpS49.89
TBVpS11.5
PEG (NY)2.11
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.97% | ||
| ROE | 13.82% | ||
| ROCE | 22.56% | ||
| ROIC | 18.58% | ||
| ROICexc | 21.59% | ||
| ROICexgc | 89.04% | ||
| OM | 20.9% | ||
| PM (TTM) | 10.85% | ||
| GM | 82.44% | ||
| FCFM | 2.5% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-10.65%
OM growth 5Y-2.1%
PM growth 3Y-25.63%
PM growth 5YN/A
GM growth 3Y-0.54%
GM growth 5Y0.2%
F-Score6
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 4.08 | ||
| Debt/EBITDA | 0.22 | ||
| Cap/Depr | 110.85% | ||
| Cap/Sales | 14.69% | ||
| Interest Coverage | 135.73 | ||
| Cash Conversion | 50.33% | ||
| Profit Quality | 23.01% | ||
| Current Ratio | 1.34 | ||
| Quick Ratio | 1.15 | ||
| Altman-Z | 4.02 |
F-Score6
WACC7.83%
ROIC/WACC2.37
Cap/Depr(3y)131.36%
Cap/Depr(5y)124.73%
Cap/Sales(3y)11.81%
Cap/Sales(5y)11.18%
Profit Quality(3y)85.87%
Profit Quality(5y)89.99%
High Growth Momentum
Growth
EPS 1Y (TTM)-10.38%
EPS 3Y-18.86%
EPS 5YN/A
EPS Q2Q%-22.76%
EPS Next Y7.55%
EPS Next 2Y7.48%
EPS Next 3Y8.47%
EPS Next 5Y3.96%
Revenue 1Y (TTM)61.09%
Revenue growth 3Y9.15%
Revenue growth 5Y5.83%
Sales Q2Q%112.35%
Revenue Next Year7.41%
Revenue Next 2Y6.57%
Revenue Next 3Y6.68%
Revenue Next 5Y3.5%
EBIT growth 1Y88.55%
EBIT growth 3Y-2.47%
EBIT growth 5Y3.61%
EBIT Next Year29.14%
EBIT Next 3Y12.56%
EBIT Next 5Y7.16%
FCF growth 1Y-80.91%
FCF growth 3Y-35.67%
FCF growth 5Y-17.46%
OCF growth 1Y4.09%
OCF growth 3Y-0.07%
OCF growth 5Y7.84%